Research summary

FDA GLP-1 Vision Loss Warning: What Is NAION and What UK Patients Should Know

Ozempic vision loss, Mounjaro eye problems and the FDA’s new safety warning explained, including UK guidance

Key Takeaways

  • FDA: On 9th November 2026, FDA included new safety information about NAION in the label of GLP-1 agonists.1
  • NAION: It is a rare disease affecting the optic nerve which causes sudden painless blindness, usually in one eye.
  • Risk: NAION has been categorised by European regulators as a very rare adverse event occurring with semaglutide and potentially occurring in 1 in 10,000 patients.4
  • UK: MHRA updated the semaglutide product information and patient information in February 2026.2
  • Mounjaro: FDA warning also covers tirzepatide, but the US labelling update does not necessarily change the UK product information.
  • Emergency: Sudden or rapidly progressing vision loss should receive urgent ophthalmological evaluation.

Quick Answer: What Is the FDA GLP-1 Vision Loss Warning?

On 9 November 2026, the US Food and Drug Administration FDA's November 2026 safety communication issued an order for GLP-1 receptor agonists' manufacturers to update their labelling to include new data regarding the possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION).1

Non-arteritic anterior ischemic optic neuropathy is an eye disease characterised by poor blood supply to the optic nerve. This leads to an acute and painless loss of vision in one eye that may lead to irreversible blindness.2

This requirement concerns all GLP-1 agonist drugs, among which there are Ozempic, Wegovy, Mounjaro and Zepbound. This regulation does not mean that the drugs are prohibited and that the majority of patients using these medications will face vision issues.

The MHRA released new guidance on semaglutide drugs in February 2026 after conducting a European review of the drugs' safety. NAION is regarded as an extremely rare adverse effect of semaglutide.3

If you suffer from unexpected loss of sight or rapid deterioration of your vision due to a GLP-1 drug, visit eye casualty or A&E without delay. Do not wait until your next appointment.

This article describes the FDA announcement, NAION symptoms, the basis of the warning issued, and what patients in the UK using Ozempic, Wegovy or Mounjaro should be aware of.

To receive personalised assistance with weight loss or discuss Medical Weight Management, please contact My Private Clinic or book Urgent & Same-Day GP Appointment.

What Did the FDA Announce on 9 November 2026?

  • The FDA official Communication released a drug safety communication for an increased risk of NAION associated with the use of GLP-1 receptor agonist drugs.1
  • The FDA mandates that companies that make these drugs include details of this potential risk in the Warnings and Precautions portion of their labelling.
  • This is a safety labelling requirement and does not indicate that the drug's approval has been withdrawn.

Why did the FDA investigate NAION?

Following this was an observational study in 2024 conducted in JAMA Ophthalmology which established a possibility of a relationship between the use of semaglutide and NAION.5

The FDA reviewed the clinical trial data, animal data, post-marketing reports and observational studies in order to determine whether the relationship could be a safety issue.

What did the FDA’s clinical trial analysis find?

Meta-analysis was performed by the FDA using 126 randomised controlled trials on GLP-1 drugs.1

FDA meta-analysis of 126 randomised controlled trials
FindingGLP-1 treatmentComparator
NAION incidence (rate per 100,000 person-years)6.4 cases3.8 cases
Probable NAION cases105
  • Fifteen NAION cases were considered probable: ten occurred in participants receiving GLP-1 medication and five in comparator participants.1
  • These numbers refer to the incidence rate calculated based on clinical trials and do not imply any probability of developing NAION for the particular patient.
  • The FDA examined observational data as well. Although some studies have shown increased risk relative to some comparators used in the treatment of diabetes, different outcomes were observed for each comparator drug.
  • In conclusion, the available data support the possibility of increased risk of rare NAION events in patients using GLP-1 medications.1
  • Nevertheless, the mechanism is still unclear, and not all drugs are equally dangerous.

Official source: FDA GLP-1 NAION Safety Communication

What Is NAION?

  • NAION means non-arteritic anterior ischemic optic neuropathy.4
  • It is a type of eye disorder that occurs as a result of decreased blood supply to the front part of the optic nerve referred to as optic disc. Decreased blood supply may affect the optic nerve and its ability to transmit visual signals from the eye to the brain.6
  • The name non-arteritic differentiates NAION from arteritic optic neuropathies which involve blood vessels with inflammation problems.
  • NAION is one of the common reasons for acute optic nerve loss of sight.

NAION symptoms

Symptoms of Nonarteritic Anterior Ischemic Optic Neuropathy are:7

  • Painless loss of vision in one eye.
  • Blurred vision.
  • Scotomas or missing parts of the visual field.
  • Loss of central visual acuity.
  • Abnormal colour vision.
  • Partial loss of the vision or shadow effect in part of the visual field.
  • In some cases, patients experience the symptoms immediately after waking up.
  • NAION does not lead to total loss of vision in most cases. Nevertheless, the damage to the optic nerve leads to irreversible vision problems.8

Loss of vision needs immediate treatment even if it is painless and partial.

What are the risk factors for NAION?

NAION can happen to individuals who are not on any GLP-1 medications.9

Known risk factors for NAION include:

  • Diabetes mellitus.
  • Hypertension.
  • Obstructive sleep apnoea.
  • Smoking.
  • Renal disease.
  • Anaemia.
  • Specific anatomical features of the optic nerve.
  • Increased age.
  • The presence of these risk factors does not automatically predispose a person to having NAION.
  • Diabetes and obesity are additional risk factors for vascular problems that need to be taken into consideration.9

If you are considering prescription weight-loss injections or experiencing side effects during treatment, consider visiting Weight loss Clinic for a comprehensive treatment plan.

How Rare Is NAION With GLP-1 Medicines?

Currently, the most compelling data on regulatory NAION issues have been reported for semaglutide.

  • Thus, in June 2025, the European Medicines Agency (EMA) decided that NAION should be regarded as a very rare adverse event associated with semaglutide therapy, which could occur in up to 1 in 10,000 patients using the drug.4
  • It was based on clinical trials and non-clinical studies, post-marketing cases and other data.
  • Some epidemiological investigations indicated that there was roughly a two-fold increase in the NAION incidence rate in adults with type 2 diabetes using semaglutide as compared with the control group.4
  • Nevertheless, relative risk and absolute risk are distinct notions.
  • In some cases, even though the relative risk is increased, the absolute number of patients who develop NAION may still be very small due to the rarity of the condition.
  • Moreover, the current evidence is characterised by certain limitations.

Source: EMA review of semaglutide and NAION

Which GLP-1 Medicines Are Covered by the FDA Warning?

The FDA safety communication dated November 2026 is applicable to medications which have the ability to act on the GLP-1 receptors.1

GLP-1 medicines and the FDA labelling requirement
Active ingredientBrand namesFDA warning
SemaglutideOzempic, Wegovy, RybelsusYes
TirzepatideMounjaro, ZepboundYes
LiraglutideSaxendaYes
Other GLP-1 receptor agonistsDepending on productCovered by the FDA requirement

The actual drugs that are available and their indications may vary between the US and UK. Read more about Weight Loss Injections for better understanding.

Ozempic vision loss

  • Ozempic is a drug containing semaglutide and used for treatment of type 2 diabetes.
  • According to the European and UK safety evaluation, one of the extremely rare side effects of semaglutide is NAION.
  • It should be stressed that it doesn’t mean that all people using Ozempic suffer from blurry vision or blindness. But any changes in vision must be evaluated immediately.4

Wegovy vision loss

  • Semaglutide is present in Wegovy, too, but it is taken to manage weight.
  • The same side effect of semaglutide causing NAION in patients is applicable in Wegovy, as well.4
  • Patients should be on the lookout for any visual problems that may develop suddenly.10

Mounjaro vision loss

  • Tirzepatide is found in Mounjaro, and it acts upon the GIP and GLP-1 receptors.11
  • Despite not being the same as semaglutide, tirzepatide has been added to the new labelling requirement by the FDA.
  • However, the FDA warning for the drug category does not mean that tirzepatide has the same drug-specific risk of NAION as semaglutide. Read more about Mounjaro in detail.

Read more about Best Weight Loss Injections for comparing your options and available treatment options.

What Is the UK Position on Ozempic, Wegovy and NAION?

  • In the UK, medicines safety information is managed by the MHRA.2
  • On 5 February 2026, the MHRA issued new information for patients and healthcare professionals regarding NAION caused by semaglutide.
  • This decision came after the European safety evaluation and recommendations of the CHM.

What does the MHRA advise patients?

According to the UK MHRA Drug Safety Update, when using semaglutide, patients should:

  • Be informed that NAION is an extremely rare possible side effect.
  • Seek immediate medical help in case of any loss of vision, even partial.
  • Visit eye casualty or A&E when suffering from any unexpected deterioration of vision.
  • Report all suspected drug side effects to the MHRA Yellow Card Scheme.

What does the MHRA advise healthcare professionals?

According to the Drug Safety Update (DSU), healthcare professionals should:2

  • Inquire about semaglutide treatment when investigating sudden visual loss.
  • Think about privately prescribed semaglutide which would not be in NHS records.
  • Ensure that ophthalmic investigation takes place at once when NAION is suspected.
  • Stop semaglutide in case of NAION diagnosis.

UK guidance: MHRA – Semaglutide and NAION

What about Mounjaro and NAION in the UK?

  • Specifically, the update in February 2026 by MHRA refers to semaglutide products.
  • FDA in its announcement in November 2026 mentions tirzepatide; however, FDA’s decision will not affect the labelling of the products in the UK.
  • MHRA can consider further evidence and provide updated guidelines where needed.
  • It would be unwise for Mounjaro patients to disregard any visual disturbances that occur abruptly just because the UK warning about semaglutide was product-specific.

What Should You Do If You Experience Vision Changes While Taking GLP-1 Medicines?

What one should do depends upon the nature of the problem being faced. Read more about NHS guidance on vision loss.

1. Sudden vision loss in one eye

  • Painless blindness, partial or complete, should be assessed immediately.
  • Report to the eye casualty or A&E and mention that you are taking medicine.

Do not wait for an appointment with your GP.

2. Rapidly worsening eyesight

  • Fast deterioration of vision is an emergency matter even if you don’t know if this deterioration is related to NAION.
  • Other eye problems can also result in similar symptoms and need another treatment.

3. Gradual blurred vision

  • Fading of vision does not necessarily imply NAION.
  • Changes in the levels of blood glucose could affect the vision temporarily among patients with diabetes.
  • Other ocular diseases including diabetic retinopathy could cause changes in vision.
  • Seek medical/ophthalmic evaluation rather than suspecting it to be due to medications' side effects.

4. Should you stop taking Ozempic or Mounjaro?

  • Do not independently alter your treatment regimen based on a news article.
  • Should NAION be identified, treatment with semaglutide needs to be stopped as per the MHRA and EMA guidelines.
  • In case you develop any other vision-related complaints, please inform your prescriber immediately.

Report a suspected side effect through Yellow Card.

Other GLP-1 Side Effects

Issues related to eyes have been brought up since NAION is known to lead to significant problems with vision.

Nevertheless, GI symptoms are some of the more frequently reported complications caused by GLP-1 drugs.12

These may include:

  • Nausea.
  • Vomiting.
  • Diarrhoea.
  • Constipation.
  • Abdominal pain.
  • Heartburn.
  • Headache.

For further details and personalised treatment read the guide to medical weight loss treatment.

What We Still Don’t Know About NAION and GLP-1 Drugs

A number of key issues need to be clarified. According to the NANOS and American Academy of Ophthalmology statement on GLP-1 receptor agonists and the risk of NAION, there are still ongoing studies on this.9 Some of the facts are as stated below:

Is NAION caused by GLP-1 drugs?

Regulatory authorities have noted an association between NAION and GLP-1 drugs, but for semaglutide, PRAC concludes there is enough data to classify it as a very rare adverse reaction. Nevertheless, the biological pathway is still not clear.4

Is Mounjaro as risky as Ozempic?

An FDA label warning on the entire class of GLP-1 receptor agonists indicates the possibility of a side effect, but this does not mean that all products carry an equal risk.

Can NAION be treated?

NAION leads to optic nerve damage which can be irreversible. At the moment, there is no effective treatment that would help restore the loss of vision.13

Will more warnings be added to Mounjaro in the UK?

Further regulatory recommendations could shift as more data emerges. It is recommended that patients and clinicians refer to the latest MHRA drug labels.

Frequently Asked Questions

Will Ozempic cause blindness?

Semaglutide is in Ozempic and has been linked to NAION, a very rare side effect. NAION may result in vision loss, but the majority of those taking Ozempic will not get this side effect. Vision loss is an urgent matter.

Does Ozempic cause eye issues?

Some people might have visual disturbances not related to NAION due to fluctuations in blood sugar. NAION is an optic nerve disease and needs to be distinguished from other causes of sudden vision loss.

Does Mounjaro lead to vision loss?

Mounjaro has been added by the FDA to their GLP-1 safety labelling due to possible NAION. However, this does not mean that Mounjaro definitely causes NAION in all cases.

Is it possible for Mounjaro to cause blindness?

NAION leads to permanent loss of vision among those who suffer from it. This condition, however, is relatively uncommon. The FDA has issued its warning with regard to the increase in risk and not necessarily about blindness.

Does Wegovy lead to blurred vision as a side effect?

Some of the factors leading to the development of blurred vision include high and low blood sugar and diseases affecting the eyes.

Is NAION a side effect of Ozempic only?

No. NAION semaglutide drug safety is pertinent to Ozempic, Wegovy, and Rybelsus. FDA Labelling Change for November 2026 includes other GLP-1 drugs such as Mounjaro and Zepbound.

Do I need to discontinue my GLP-1 medication?

Do not stop prescribed treatment independently because of media reports. If NAION is confirmed, semaglutide should be discontinued in accordance with regulatory guidance. For other symptoms or concerns, consult your prescribing clinician.

Does the FDA warning apply to UK patients?

FDA controls medication in the US. Medication safety issues in the UK are handled by the MHRA. The UK has already revised information about semaglutide concerning NAION. The FDA’s new labelling policy does not imply that the information for UK products would be altered.

Which patients are at risk of developing NAION?

NAION is usually more prevalent in the elderly, especially those suffering from diabetes, hypertension, obstructive sleep apnoea, and renal dysfunction. However, being affected by these risks does not imply that one develops NAION.

Concerned About Your Medication or Vision?

Should you be currently on medication like Ozempic, Wegovy, or Mounjaro and you have issues related to your medication, booking a GP assessment may give you clarity on your symptoms and how to proceed further.

We at My Private Clinic Preston offer private GP consultations and you will be able to consult with Dr Faizal Secretary, a GMC registered GP.

Consultations could take the form of:

No registration is required; with your consent, we can also get access to your NHS records, and you continue to remain registered with your NHS GP.

If you experience sudden vision loss, don't waste time booking a private GP appointment. Go to eye casualty or A&E immediately.

This article provides general information only and is not considered medical advice of any sort. Please consult an appropriate healthcare professional.

References

  1. US Food and Drug Administration. FDA requires safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) due to potential increased risk of rare but serious eye condition. FDA Drug Safety Communication. November 9, 2026. Accessed November 12, 2026. fda.gov
  2. Medicines and Healthcare products Regulatory Agency. Semaglutide (Wegovy, Ozempic and Rybelsus): risk of non-arteritic anterior ischemic optic neuropathy (NAION). Drug Safety Update. February 5, 2026. Accessed November 12, 2026. gov.uk
  3. Medicines and Healthcare products Regulatory Agency. MHRA updates guidance for semaglutide prescribers and patients. GOV.UK. February 5, 2026. Accessed November 12, 2026. gov.uk
  4. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 6, 2025. Accessed November 12, 2026. ema.europa.eu
  5. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. doi:10.1001/jamaophthalmol.2024.2296 PMID 38958939
  6. NAION: diagnosis and management. EyeNet Magazine. American Academy of Ophthalmology. August 1, 2022. Accessed November 12, 2026. aao.org
  7. Kaur K, Margolin E. Nonarteritic anterior ischemic optic neuropathy. In: StatPearls. StatPearls Publishing; 2025. PMID 32644471
  8. Salvetat ML, Pellegrini F, Spadea L, Salati C, Zeppieri M. Non-arteritic anterior ischemic optic neuropathy (NA-AION): a comprehensive overview. Vision (Basel). 2023;7(4):72. doi:10.3390/vision7040072 PMID 37987292
  9. North American Neuro-Ophthalmology Society, American Academy of Ophthalmology. Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: a consensus statement by NANOS and the American Academy of Ophthalmology. May 2026. Accessed November 12, 2026. aao.org
  10. Novo Nordisk Limited. Wegovy 1 mg FlexTouch solution for injection in pre-filled pen: summary of product characteristics. Electronic medicines compendium (emc). Accessed November 12, 2026. emc
  11. Eli Lilly and Company Limited. Mounjaro KwikPen solution for injection in pre-filled pen: summary of product characteristics. Electronic medicines compendium (emc). Accessed November 12, 2026. emc
  12. Novo Nordisk Limited. Ozempic solution for injection in pre-filled pen: summary of product characteristics. Electronic medicines compendium (emc). Accessed November 12, 2026. emc
  13. Kinori M, Ben-Bassat I, Wasserzug Y, Chetrit A, Huna-Baron R. Visual outcome of mega-dose intravenous corticosteroid treatment in non-arteritic anterior ischemic optic neuropathy: retrospective analysis. BMC Ophthalmol. 2014;14:62. doi:10.1186/1471-2415-14-62 PMID 24886579

Regulatory notices were read at source, and journal records checked against PubMed, on 12 November 2026.